Pfizer Inc. Chief Executive Officer Albert Bourla pocketed about $5.6 million after selling stock, the latest executive to reap the rewards of insider share transactions after recent COVID 19 vaccine breakthroughs.

Bourla is one of many pharmaceutical executives who made deals under prearranged 10b5-1 trading plans, which let people schedule sales in advance at certain times or prices, absolving themselves from accusations of insider trading. Public-company executives typically receive a considerable share of their compensation in the form of stock, and the vast majority periodically sell part of their holdings.

Guest:Dr. Mandla Lamba - CEO | Verityhurst Capital